Summit Therapeutics Inc. - COM (SMMT)

CUSIP: 86627T108

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class
Equity / COM
Total 13F shares
11,033,765
Share change
+68,101
Total reported value
$29,678,000
Put/Call ratio
42%
Price per share
$2.69
Number of holders
49
Value change
+$54,239
Number of buys
21
Number of sells
24

Quarterly Holders Quick Answers

What is CUSIP 86627T108?
CUSIP 86627T108 identifies SMMT - Summit Therapeutics Inc. - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Summit Therapeutics Inc. - COM (SMMT) as of Q4 2021

As of 31 Dec 2021, Summit Therapeutics Inc. - COM (SMMT) was held by 49 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 11,033,765 shares. The largest 10 holders included Polar Capital Holdings Plc, BlackRock Inc., VANGUARD GROUP INC, BAILLIE GIFFORD & CO, MORGAN STANLEY, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, Russell Investments Group, Ltd., NORTHERN TRUST CORP, and UBS Group AG. This page lists 49 institutional shareholders reporting positions in this security for the Q4 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.